News Brief
Mumbai-Based Haffkine Biopharma To Produce 22.8 Crore Doses Per Annum Of Bharat Biotech's Covaxin
Bharat Biotech’s COVAXIN, India’s first indigenous vaccine against coronavirus. (Swarajya Magazine)
The Centre on Wednesday (2 June) said that it has taken steps to accelerate domestic vaccine production for the massive ongoing Covid vaccination drive.
Mumbai-based Haffkine Biopharma will produce 22.8 crore doses per annum of Covaxin under technology transfer arrangement with Bharat Biotech, the Science and Technology Ministry said on Wednesday.
With the aim of vaccinating the entire eligible population at the earliest, domestic vaccine production is being steadily ramped up in the country with the help from the Centre, it said.
As part of this initiative, three public enterprises are being supported by the Department of Biotechnology under Atmanirbhar Bharat 3.0 Mission 'Covid Suraksha'.
These enterprises are the Haffkine Biopharmaceutical Corporation Ltd in Mumbai, Indian Immunologicals Ltd in Hyderabad and Bharat Immunologicals and Biologicals Ltd, in Uttar Pradesh's Bulandshahr.
Haffkine Biopharma, a Maharashtra state PSU is getting ready to manufacture Covaxin under technology transfer arrangement with Hyderabad-based Bharat Biotech Ltd. The production will take place at the Parel complex of the company.
Sandeep Rathod, Managing Director of Haffkine BioPharma said the company proposes to produce 22.8 crore doses of Covaxin in a year. "For undertaking production of Covaxin, Haffkine Biopharma has been provided with Rs 65 crore grant by the Centre and Rs 94 crore from the Government of Maharashtra," he added.
"We have been given a timeline of eight months and the work is being executed on a war footing. The vaccine production process involves two stages -- drug substance and final drug product. For production of drug substance we need to build a Bio Safety Level 3 (BSL 3) facility, while Haffkine already has the Fill Finish facility", said Rathod.
BSL 3 is a safety standard applicable to such facilities where work involves microbes which can cause serious disease via inhalation route.
"Enhancing vaccine production capacity using Public sectors assets will go a long way in building production capacity of vaccines in our country to support the massive vaccination drive," said Dr Renu Swarup, Secretary Department of Biotechnology and Chairperson BIRAC (Biotechnology Industry Research Assistance Council).
Haffkine BioPharmaceutical Corporation Ltd is an offshoot of the 122-year-old Haffkine Institute, which is one of the oldest biomedical research institutes in the country, named after the Russian bacteriologist Dr Waldemar Haffkine, who invented the plague vaccine.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
